Recent developments in the science of human longevity have brought renewed attention to the multi-ingredient nutritional supplement NOVOS Core. In a randomized, double-blind, placebo-controlled clinical trial recently published in the European Heart Journal Open, researchers observed that daily consumption of the longevity-marketed supplement was associated with substantial enhancements in vascular function, reductions in arterial stiffness, and a significant drop in systolic blood pressure over a six-month period.

Led by Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey, the study evaluated whether a complex blend of compounds designed to target multiple biological hallmarks of aging could positively influence cardiovascular metrics in healthy adults. While the results have generated considerable excitement within the scientific and longevity research communities, independent experts emphasize the necessity for cautious interpretation and independent replication, citing notable methodological limitations such as participant attrition and demographic discrepancies between the study groups.

Understanding the Mechanics of Vascular Aging

As the human body ages, the cardiovascular system undergoes structural and functional transformations that elevate the risk of cardiovascular disease—the leading cause of mortality worldwide. Central to this decline is the endothelium, the delicate single-cell inner lining of blood vessels. Healthy endothelial cells constantly monitor changes in blood flow and release signaling molecules, such as nitric oxide, that prompt surrounding vascular smooth muscle to relax, thereby accommodating increased blood volume.

With advancing age, however, the endothelium typically loses its responsiveness. Arteries experience progressive stiffening, driven by chronic low-grade inflammation, oxidative stress, and mitochondrial dysfunction within vascular tissues. This arterial stiffening forces the heart to work harder to circulate blood, frequently manifesting clinically as rising systolic blood pressure.

NOVOS Core was formulated to counteract these interconnected processes. The supplement is a complex, multi-ingredient powder containing glycine, calcium alpha-ketoglutarate, glucosamine sulfate, magnesium malate, vitamin C, L-theanine, fisetin, pterostilbene, hyaluronic acid, lithium aspartate, and extracts of rhodiola and ginger. According to the manufacturing company, these constituents were selected based on pre-existing literature regarding their individual impacts on cellular longevity pathways. Nevertheless, the clinical trial evaluated the comprehensive mixture as a singular intervention, leaving open questions regarding which specific ingredients—or synergistic combinations thereof—drove the observed physiological improvements.

Study Design and Chronology of the Trial

The clinical investigation followed a rigorous randomized, double-blind, placebo-controlled design. NOVOS provided the active supplement and a visually and gustatorily matching placebo, alongside financial support for the study.

The trial enrolled 61 generally healthy, non-smoking adult participants with no history of unstable cardiovascular disease. Participants were randomly allocated to receive either a daily 15-gram dose of the active powder or the placebo.

A notable initial limitation highlighted by reviewers was a baseline age discrepancy between the cohorts. The control group was older on average, registering at 60 years compared to 53 years for the supplement group at enrollment (and 59 versus 54 among those retained for the primary analysis). Baseline blood pressure readings averaged 128/75 mmHg for the intervention group and 125/75 mmHg for the controls, indicating that the cohort did not suffer from severe hypertension.

The research team tracked cardiovascular metrics across three distinct chronological milestones to capture both immediate and sustained physiological reactions:

  1. Baseline assessment immediately preceding the first dose.
  2. Acute response evaluation exactly one hour following the initial dose.
  3. Long-term follow-up assessment conducted six months later, scheduled 24 hours after the most recent dose to minimize residual acute pharmacological effects.

Attrition rates throughout the six-month study period were substantial. Only 43 participants completed the protocol and were included in the primary analysis—24 in the supplement arm and 19 in the placebo arm. While the reasons for the dropouts were largely unexplained, such a high rate of attrition introduces the potential for selection bias, potentially altering the compositional balance of the groups over time.

Key Findings: Vascular Function and Blood Pressure Metrics

Despite the study’s limitations, the primary and secondary endpoints revealed striking physiological shifts in the group receiving the multi-component supplement.

The primary endpoint of the trial was flow-mediated dilation (FMD), a standard non-invasive ultrasound measure of endothelial function reflecting how significantly an arm artery widens after the release of a temporary blood pressure cuff occlusion. At the six-month mark, FMD increased by an average of 2.6 percentage points in the supplement group—surging from approximately 5.5% to 8.1%—while remaining virtually unchanged in the placebo cohort. When adjusted for baseline covariates, the relative improvement stood at 2.9 percentage points. Interestingly, an acute increase of 3.4 percentage points was recorded just one hour after the very first dose, pointing to a rapid biological interaction with vascular tissues.

Secondary measurements focused on pulse wave velocity (PWV), an indicator of arterial stiffness determined by measuring the speed at which a pressure pulse travels through the arterial tree. Stiffer arteries transmit these waves more rapidly. After six months of daily supplementation, PWV decreased by 0.78 meters per second in the intervention group, whereas it increased by 0.56 meters per second in the control group, resulting in an adjusted between-group difference of -1.18 m/s. While acute changes in PWV trended positively for the supplement group on day one, they did not reach statistical significance, implying that structural reductions in arterial stiffness require prolonged intervention.

Furthermore, systolic blood pressure demonstrated a pronounced decline. At the six-month evaluation, participants taking NOVOS Core experienced an average drop in systolic blood pressure of 8.5 mmHg, compared to a reduction of 1.5 mmHg in the placebo group. The adjusted net difference was 6.1 mmHg. Diastolic blood pressure, however, showed no statistically significant divergence between the two groups.

Blood lipid panels—including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides—remained statistically comparable across both cohorts at the conclusion of the trial. This absence of lipid modulation indicates that improvements in vascular health operated independently of traditional cholesterol pathways. Consequently, calculated ten-year cardiovascular risk scores showed a modest improvement relative to placebo, primarily driven by the reduction in systolic blood pressure.

Expert Reactions and Analytical Perspectives

The publication of these findings has prompted active discussion among cardiovascular specialists and longevity researchers.

"Our hypothesis in this study was whether a multi-component supplement addresses many biological and biochemical processes related to vascular aging and has an effect on measures of vascular health," Professor Christian Heiss stated in an institutional release. "We found favourable changes in endothelial function, arterial stiffness and systolic blood pressure after six months."

Dr. Brad Stanfield, a New Zealand-based longevity physician not involved in the trial, expressed surprise at the magnitude of the physiological response. "It’s an exciting result, but the effect size is surprisingly large," Stanfield noted in an interview. He pointed out that the nearly 3-percentage-point rise in FMD is "more than double what cocoa flavanols achieved in this same research group’s earlier trials."

At the same time, Stanfield urged caution regarding clinical extrapolation. "FMD is also a surrogate: people with better scores have fewer heart attacks, but I’m not aware of any trial showing that raising it with a treatment prevents them. The 6-mmHg drop in systolic blood pressure would matter more, if it holds up." He added that the methodological constraints demand independent verification: "With nearly a third of participants lost to follow-up and a control group seven years older, I’d want an independent group to replicate this before drawing conclusions."

Broader Implications for Longevity Interventions

The trial highlights an emerging methodological shift in biogerontology: testing broad-spectrum, multi-ingredient formulations designed to target multiple aging mechanisms simultaneously, rather than isolating single molecules. While pharmaceutical research traditionally favors single-target interventions to satisfy regulatory pathways, the supplement industry increasingly explores combination approaches modeled after complex dietary patterns.

Nevertheless, the study underscores the persistent challenges inherent in nutritional intervention trials. Issues such as participant adherence, high attrition rates, and confounding demographic variables can complicate data interpretation. Additionally, because the trial administered NOVOS Core as an integrated formula, it remains impossible to determine whether all eleven active ingredients contributed equally, or if a select few compounds drove the entirety of the clinical benefit.

As interest in preventative cardiology and healthspan extension continues to accelerate, the scientific community anticipates that these findings will prompt larger, longer-duration, and more rigorously controlled independent trials. Until such replications are completed and clinical endpoints—such as the actual incidence of cardiovascular events—are directly measured, the long-term clinical utility of multi-component longevity supplements remains an area of active investigation.